• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Aptose Biosciences, Inc. - Common Shares (TSX:APS)

    2.260 +0.030 (+1.35%)
    Streaming Delayed Price Updated: 9:58 AM EST, Dec 8, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,894
    Open 2.260
    Bid (Size) 2.260 (83)
    Ask (Size) 2.340 (50)
    Prev. Close 2.230
    Today's Range 2.260 - 2.260
    52wk Range 0.1550 - 5.800
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical
    Aptose Biosciences minority shareholders to receive C$2.41 in cash per share in a “go private” transaction 
    From Aptose Biosciences, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +584.8%
    +584.8%
    1 Month
    +20.2%
    +20.2%
    3 Month
    +33.7%
    +33.7%
    6 Month
    -5.8%
    -5.8%
    1 Year
    +679.3%
    +679.3%

    More News

    Read More
    News headline image
    Aptose Reports Third Quarter 2025 Results
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose and Hanmi Pharmaceutical Extend Loan Agreement to Continue Development of Tuspetinib in Triplet Therapy for AML
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose Reports Second Quarter 2025 Results
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its Shareholders
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose Receives Second Advance under the Loan Agreement with Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose Upgraded to Trade on OTCQB Market
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose Announces Deferral of Interest Payment
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose Provides Corporate Updates
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose Announces Results from Annual and Special Meeting of Shareholders
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose Reports First Quarter 2025 Results
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose Announces Auditor Not Standing for Re-Appointment
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose Common Shares to Delist from Nasdaq as of April 2, 2025
    From Aptose Biosciences, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Aptose Biosciences, Inc. - Common Shares publicly traded?
    Yes, Aptose Biosciences, Inc. - Common Shares is publicly traded.
    What exchange does Aptose Biosciences, Inc. - Common Shares trade on?
    Aptose Biosciences, Inc. - Common Shares trades on the Toronto Stock Exchange
    What is the ticker symbol for Aptose Biosciences, Inc. - Common Shares?
    The ticker symbol for Aptose Biosciences, Inc. - Common Shares is APS on the Toronto Stock Exchange
    What is the current price of Aptose Biosciences, Inc. - Common Shares?
    The current price of Aptose Biosciences, Inc. - Common Shares is 2.260
    When was Aptose Biosciences, Inc. - Common Shares last traded?
    The last trade of Aptose Biosciences, Inc. - Common Shares was at 12/08/25 09:58 AM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.